Targeted Strategies for Today's Evolving Markets

MissionIR Blog

BioSpecifics Technologies (BSTC) Presents at Rodman & Renshaw Conference

BioSpecifics Technologies Corp. (NASDAQ: BSTC) is a profitable, commercial-stage biopharmaceutical company that has developed injectable collagenase for 12 clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and abroad for the treatment of adult Dupuytren’s contracture patients with up to two palpable cords in the same palm, and for Peyronie’s disease in men with a palpable plaque and a curvature of 30 degrees or greater at the start of therapy. For more information, visit the company’s website at

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit
This entry was posted in Rodman and Renshaw Conference. Bookmark the permalink.

Comments are closed.